These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
142 related articles for article (PubMed ID: 22222451)
1. The use of molecular graphics in structure-based drug design. Emsley P; Debreczeni JE Methods Mol Biol; 2012; 841():143-59. PubMed ID: 22222451 [TBL] [Abstract][Full Text] [Related]
2. A medicinal chemistry perspective on structure-based drug design and development. Maddaford SP Methods Mol Biol; 2012; 841():351-81. PubMed ID: 22222460 [TBL] [Abstract][Full Text] [Related]
3. Accounting for solvent in structure-based drug design. Tari LW Methods Mol Biol; 2012; 841():251-66. PubMed ID: 22222456 [TBL] [Abstract][Full Text] [Related]
4. Crystallization to obtain protein-ligand complexes for structure-aided drug design. Danley DE Acta Crystallogr D Biol Crystallogr; 2006 Jun; 62(Pt 6):569-75. PubMed ID: 16699182 [TBL] [Abstract][Full Text] [Related]
8. The utility of structural biology in drug discovery. Tari LW Methods Mol Biol; 2012; 841():1-27. PubMed ID: 22222446 [TBL] [Abstract][Full Text] [Related]
9. Substrate selectivity of drug-metabolizing cytochrome P450s predicted from crystal structures and in silico modeling. Dong D; Wu B Drug Metab Rev; 2012 Feb; 44(1):1-17. PubMed ID: 22242930 [TBL] [Abstract][Full Text] [Related]
10. Pharmacophore modeling and applications in drug discovery: challenges and recent advances. Yang SY Drug Discov Today; 2010 Jun; 15(11-12):444-50. PubMed ID: 20362693 [TBL] [Abstract][Full Text] [Related]
11. CORES: an automated method for generating three-dimensional models of protein/ligand complexes. Hare BJ; Walters WP; Caron PR; Bemis GW J Med Chem; 2004 Sep; 47(19):4731-40. PubMed ID: 15341488 [TBL] [Abstract][Full Text] [Related]
12. High-throughput X-ray crystallography for drug discovery. Blundell TL; Patel S Curr Opin Pharmacol; 2004 Oct; 4(5):490-6. PubMed ID: 15351354 [TBL] [Abstract][Full Text] [Related]
13. Structure-based quantitative structure--activity relationship modeling of estrogen receptor β-ligands. Dong X; Hilliard SG; Zheng W Future Med Chem; 2011 Jun; 3(8):933-45. PubMed ID: 21707397 [TBL] [Abstract][Full Text] [Related]
14. Informatics and modeling challenges in fragment-based drug discovery. Hubbard RE; Chen I; Davis B Curr Opin Drug Discov Devel; 2007 May; 10(3):289-97. PubMed ID: 17554855 [TBL] [Abstract][Full Text] [Related]
15. Metal complexes in medicinal chemistry: new vistas and challenges in drug design. Thompson KH; Orvig C Dalton Trans; 2006 Feb; (6):761-4. PubMed ID: 16437168 [TBL] [Abstract][Full Text] [Related]
16. Atomic property fields: generalized 3D pharmacophoric potential for automated ligand superposition, pharmacophore elucidation and 3D QSAR. Totrov M Chem Biol Drug Des; 2008 Jan; 71(1):15-27. PubMed ID: 18069986 [TBL] [Abstract][Full Text] [Related]